ARVO

In a poster presented at the Association for Research in Vision and Ophthalmology’s 2022 annual meeting, Osama Ibrahim Hirayama, MD, and colleagues offered results that demonstrating that anisometropia and astigmatic error were greater among the patients with high myopia compared with the other groups. Compared with the subjects with no myopia, those with high myopia reported significantly more dryness, less photophobia, and less pain.

Dr. David Bingaman of Ora Clinical discusses today’s need to accelerate clinical studies and increase investments in retina and challenging disease states.

The axitinib intravitreal implant (OTX-TKI) is being evaluated to treat wet age-related macular degeneration in a phase 1b clinical trial.

Investigators from the New York University Grossman School of Medicine presented data at the ARVO 2022 annual meeting that concluded mapping of the relative cerebrovascular reactivity in the murine brain showed widespread brain changes resulting from the chronic IOP elevation and demonstrates vascular involvement in glaucoma both within and beyond the primary visual pathways.

At ARVO 2022, Jason S. Slakter, MD, presents data on the efficacy and safety of OPT-302 when combined with ranibizumab for polypoidal choroidal vasculopathy.

In a poster presented at the Association for Research in Vision and Ophthalmology’s 2022 annual meeting in Denver, Mamoru Ogawa, MD, noted that investigators have found that the choroidal and central corneal thicknesses increased over a very short period of time following intensive outdoor activity.

Results from our recent poll regarding ARVO 2022 attendance indicate that most ophthalmologists and retina specialists plan to participate in the Annual Meeting in person in Denver, Colorado.

A poll for retina specialists regarding their attendance at the Association for Research in Vision and Ophthalmology 2022 Meeting in Denver, Colorado. This poll is now closed.

Mark Pennesi, MD, PhD, reports during ARVO 2021 that preliminary results have shown that AGTC-401 and AGTC-402 seem safe and well tolerated in patients with ACHM.

In a presentation at ARVO, Friederike Kortuem, MD, MSc, explains that treatment with voretigene neparvovec-rzyl led to a short-term change in the foveal morphology in a patient with visual impairment that included nyctalopia and decreased visual acuity in early childhood.

Michael A. Singer, MD, speaks on the highlights of his presentation focusing on IOP in the PALADIN 24-month data intravitreal steroid (ILUVIEN).

Theodore Leng, MD, discusses the highlights from his presentation on "AAO IRIS Registry Data Replicates VIEW 1 and VIEW 2 Clinical Trial Outcome Data," during the virtual 2021 ARVO meeting.

Michael Mbagwu, MD, speaks on the highlights of his virtual 2021 ARVO presentation regarding the development of an algorithm tool that links patient imaging to their clinical data, specifically within the AAO IRIS Registry.

Daniel F. Kiernan, MD, discusses key findings of a clinical study analyzing the effect of dexamethasone intracameral drug-delivery suspension on macular thickness based on OCT testing following vitreoretinal surgery.

Clinicians' knowledge of the epidemiology, natural history, causal mechanisms, and treatments for diabetic retinopathy (DR) has evolved dramatically over recent decades.

EYS809, a non-viral gene therapy sustained drug-delivery product that delivers anti-vascular endothelial growth factor to the eye, may replace the need for repeated intravitreal anti-VEGF injections and improve vision in patients diagnosed with wet age-related macular degeneration.

Logan Vander Woude, DO, MPH, examines research on improved resolution of symptomatic vitreomacular traction as an attempt to further refine the potential factors predictive of better outcomes.

Glenn J. Jaffe, MD, discusses the key points of his virtual presentation on targeting neurodegenerative diseases with risuteganib, minimizing damage to the retina when compromised, and the need for newer treatment therapies to target different pathways.

Robyn Guymer, PhD, MBBS, highlights the latest trial results for faricimab, the first bispecific antibody designed for intraocular use in treating patients with neovascular age-related macular degeneration.

Sunil Srivastava, MD, examines why and how optical coherence tomography characteristics may be predictive of the efficacy of the injections.

Bryce Buchowicz, MD, outlines roadblocks to timely diagnosis of central retinal artery occlusion and treatment with tissue plasminogen activator during a virtual presentation at ARVO.

Logan Vander Woude, DO, MPH, takes a deeper dive into symptomatic vitreomacular traction research in an attempt to further refine the potential factors predictive of better outcomes.

Investigators offer insight on how patients with BRVO or CRVO with any lapse in treatment of 3 months or longer are at risk for poorer outcomes.

Steffen E. Künzel, MD, discusses the key points of his research presentation regarding low vulnerability of the posterior eye segment to SARS-CoV-2 infection.

Uwe Oberheide, MD, discusses the key findings of his virtual ARVO 2021 presentation on modeling of IOLs for patients with AMD by ray-tracing.

John Wells, MD, presents efficacy, durability, and safety findings from phase 3 YOSEMITE and RHINE trials during the virtual ARVO meeting.

Let the countdown begin for May as ‘month of ARVO’ and Annual Meeting

Results of a prospective trial show the tool is ready for clinical use and potential deployment for remote telemedical use.

Researchers advocate for intraoperative intravitreal steroid during cataract surgery in patients with DME.

A study suggests this user-friendly platform may be useful as a supplemental visual function measure in patients with AMD.